NCT07068282View on ClinicalTrials.gov

The Effect of Novel D3 Use as a Mouthwash in COVID-19 Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

January 25, 2025

Study Completion Date

February 12, 2025

Conditions
Corona Virus Disease 19 (COVID-19)
Interventions
DRUG

Cholecalciferol (vitaminD3)

Vitamin D3 mouthwash was prepared for COVID-19 participants, to compare between the saliva only (control group), and with the use of mouthwash in saliva after the participants swish for 60 seconds (experimental group) and compare the effect of vitamin D over the virus in saliva, from both groups by testing via RAT and R-PCR.

Trial Locations (1)

Unknown

KingFaisal, Jeddah

All Listed Sponsors
lead

King Faisal Specialist Hospital & Research Center

OTHER

NCT07068282 - The Effect of Novel D3 Use as a Mouthwash in COVID-19 Patients | Biotech Hunter | Biotech Hunter